1,100 results on '"Yang, J.C."'
Search Results
52. Overview of current systemic management of EGFR-mutant NSCLC
53. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
54. Measurements on the gas desorption yield of the oxygen-free copper irradiated with low-energy [formula omitted] and [formula omitted]
55. Dielectronic recombination experiments at the storage rings: From the present CSR to the future HIAF
56. HIAF: New opportunities for atomic physics with highly charged heavy ions
57. Measurement of the lifetime and the proportion of 12C3+ ions in stored relativistic ion beams as a preparation for laser cooling experiments at the CSRe
58. Pressure profiles of the BRing based on the simulation used in the CSRm
59. The calibration of elastic scattering angular distribution at low energies on HIRFL-RIBLL
60. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
61. DISCHARGE CHARACTERISTICS OF CRYOGENIC FLUIDS FROM A PRESSURIZED VESSEL
62. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
63. Longitudinal electron cooling experiments at HIRFL-CSRe
64. Electron cooling system in the booster synchrotron of the HIAF project
65. Cardiac Events in Breast Cancer Patients Treated with Modern Radiotherapy
66. 384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)
67. Cardiotoxicity in Patients with Ductal Carcinoma In Situ (DCIS) in the Contemporary Radiotherapy Era
68. 321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION
69. Incidence of Radiation Pneumonitis after a Single 550 cGy Fraction of Total Body Irradiation: Single Institutional Experience
70. LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)
71. 319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC
72. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
73. EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib
74. OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100
75. OA12.06 First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results
76. 988P Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)
77. LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial
78. EP08.01-028 Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer
79. EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
80. EP08.02-029 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
81. LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
82. LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
83. 987P Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: Preliminary analysis of WU-KONG6, the first pivotal study
84. OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
85. Calcium hydroxyapatite/whitlockite obtained from dairy products: Simple, environmentally benign and green preparation technology
86. Impact of interpersonal relationships and acquired capability for suicide on suicide attempts: An observational study
87. Design of a compact structure cancer therapy synchrotron
88. Time-of-flight detectors with improved timing performance for isochronous mass measurements at the CSRe
89. A timing detector with pulsed high-voltage power supply for mass measurements at CSRe
90. High Intensity heavy ion Accelerator Facility (HIAF) in China
91. Performance of the resonant Schottky pickup at CSRe
92. YAP:Ce and CsI(Tl) detectors for dielectronic recombination experiment at the CSRm
93. Status of the HIRFL–CSR complex
94. Calculation of half-lives of cluster decay by using proximity potential with a new universal function
95. 55P The impact of liquid next-generation testing timing on treatment-naïve advanced non-small cell lung cancer: A prospective observational study
96. 25P Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping
97. 12P A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs
98. 29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results
99. Precision measurement of the transition energy γt versus magnetic rigidity for storage-ring isochronous mass spectrometry
100. Net global warming potential and greenhouse gas intensity of annual rice–wheat rotations with integrated soil–crop system management
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.